McPherson Clifton, Chubet Richard, Holtz Kathy, Honda-Okubo Yoshikazu, Barnard Dale, Cox Manon, Petrovsky Nikolai
Protein Sciences Corporation Inc, Meriden, CT, USA.
Vaxine Pty Ltd, 1 Flinders Drive, Bedford Park, Adelaide, 5042, Australia.
Methods Mol Biol. 2016;1403:269-84. doi: 10.1007/978-1-4939-3387-7_14.
Given periodic outbreaks of fatal human infections caused by coronaviruses, development of an optimal coronavirus vaccine platform capable of rapid production is an ongoing priority. This chapter describes the use of an insect cell expression system for rapid production of a recombinant vaccine against severe acute respiratory syndrome coronavirus (SARS). Detailed methods are presented for expression, purification, and release testing of SARS recombinant spike protein antigen, followed by adjuvant formulation and animal testing. The methods herein described for rapid development of a highly protective SARS vaccine are equally suited to rapid development of vaccines against other fatal human coronavirus infections, e.g., the MERS coronavirus.
鉴于冠状病毒会引发致命的人类感染周期性爆发，开发一个能够快速生产的最佳冠状病毒疫苗平台仍是当前的首要任务。本章描述了使用昆虫细胞表达系统快速生产针对严重急性呼吸综合征冠状病毒（SARS）的重组疫苗。文中详细介绍了SARS重组刺突蛋白抗原的表达、纯化及放行检测方法，随后是佐剂配方和动物试验。本文所述的快速开发高保护性SARS疫苗的方法同样适用于快速开发针对其他致命人类冠状病毒感染的疫苗，例如中东呼吸综合征冠状病毒。
